Open AccessPresence of bone marrow micro‐metastases in stage I‐III colon cancer patients is associated with worse disease‐free and overall survival
Author(s) -
Viehl Carsten T.,
Weixler Benjamin,
Guller Ulrich,
DellKuster Salome,
Rosenthal Rachel,
Ramser Michaela,
Banz Vanessa,
Langer Igor,
Terracciano Luigi,
Sauter Guido,
Oertli Daniel,
Zuber Markus
Publication year - 2017
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1056
Subject(s) - medicine , hazard ratio , colorectal cancer , stage (stratigraphy) , proportional hazards model , prospective cohort study , bone marrow , cancer , oncology , cohort , gastroenterology , confidence interval , surgery , paleontology , biology
The prognostic significance of bone marrow micro‐metastases ( BMM ) in colon cancer patients remains unclear. We conducted a prospective cohort study with long‐term follow‐up to evaluate the relevance of BMM as a prognostic factor for disease free ( DFS ) and overall survival ( OS ) in stage I‐ III colon cancer patients. In this prospective multicenter cohort study 144 stage I‐ III colon cancer patients underwent bone marrow aspiration from both iliac crests prior to open oncologic resection. The bone marrow aspirates were stained with the pancytokeratin antibody A45‐B/B3 and analyzed for the presence of epithelial tumor cells. DFS and OS were analyzed using a Cox proportional hazard model and robust standard errors to account for clustering in the multicenter setting. Median overall follow‐up was 6.2 years with no losses to follow‐up, and 7.3 years in patients who survived. BMM were found in 55 (38%) patients. In total, 30 (21%) patients had disease recurrence and 56 (39%) patients died. After adjusting for known prognostic factors, BMM positive patients had a significantly worse DFS (hazard ratio [ HR ] 1.33; 95% confidence interval [95% CI ]: 1.02‐1.73; P = 0.037) and OS ( HR 1.30; 95% CI : 1.09‐1.55; P = 0.003) compared to BMM negative patients. Bone marrow micro‐metastases occur in over one third of stage I‐ III colon cancer patients and are a significant, independent negative prognostic factor for DFS and OS . Future trials should evaluate whether node‐negative colon cancer patients with BMM benefit from adjuvant chemotherapy.